WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy

Exploiting dendritic cells in the development of cancer vaccines

(2013) Laura Bracci et al.   Expert Review of Vaccines

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

(2013) T Maeda et al.   Blood Cancer Journal

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions

(2012) E. M. Tyler et al.   BLOOD

Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy

(2011) Katayoun Rezvani et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission

(2011) Y Hashii et al.   LEUKEMIA

Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease

(2011) A Tsuboi et al.   LEUKEMIA

Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia

(2011) Ulrike Bacher et al.   TheScientificWorldJOURNAL

Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation

(2010) Nicolaus Kröger et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

(2010) P. G. Maslak et al.   BLOOD

Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol

(2010) A. Gaiger et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy

(2010) H. Sugiyama   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome

(2009) Masaki Yasukawa et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostic impact ofWT1mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

(2009) Verena Ingeborg Gaidzik et al.   BLOOD

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

(2009) U. Keilholz et al.   BLOOD

Induction of Wilms' Tumor Protein (WT1)-Specific Antitumor Immunity Using a Truncated WT1-Expressing Adenovirus Vaccine

(2009) T. Osada et al.   CLINICAL CANCER RESEARCH

Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation

(2008) Katayoun Rezvani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells

(2008) J. Greiner et al.   CLINICAL CANCER RESEARCH

Quantitative assessment ofWT1gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia

(2008) Anna Candoni et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

(2008) D. Cilloni et al.   HAEMATOLOGICA

Mutation of the Wilms’ Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party

(2008) Priya Virappane et al.   JOURNAL OF CLINICAL ONCOLOGY

Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2008) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY